IFN-α has been shown to elicit antitumor activity in carcinoid tumors. In the present study the effects of IFN-α on the protein expression involved in the IFN-α signaling, which were recognized as signal transducer and activators of transcription (Stats), were investigated. Archive specimens from 45 carcinoid patients, 33 before IFN-α and 45 during treatment, were studied. The tissues were immunostained for protein expression by using monoclonal anti-Stat1 and anti-Stat2 antibodies. Results showed that Stat1 and Stat2 immunostaining were significantly increased during IFN-α treatment. Stats scores were significantly increased only in patients with objective response as well as those with stable disease but not in those with progressive disease. The induction of Stats correlated with the survival rates of the patients. In addition, both Stat scores significantly correlated with the p68 protein expression. In a carcinoid tumor cell line, Bon1, IFN-α dose-dependently increased the Stat expression. Analysis of cell fractions showed that IFN-α increased Stat protein both in cytoplasm and nucleoplasm of the cells. Furthermore, IFN-α enhanced tyrosine phosphorylation of Stat1 and Stat2. Thus, the antitumor effect, in vivo and in vitro, in IFN-α-treated carcinoid tumors seems to be mediated via upregulation of Stat proteins and enhancement of phosphorylation of these proteins.

Keywords:
Interferon-α, Signal transduction, Phosphorylation, Carcinoid tumor, Stat1, Stat2
1.
Taniguchi T: Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251–255.
2.
Pestka S: The interferon receptors. Semin Oncol 1997;24:S9–18, S19–40.
3.
Hoey T, Schindler U: STAT structure and function in signaling. Curr Opin Genet Dev 1998;8:582–587.
4.
Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC, Rosen ST: Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998;91:570–576.
5.
Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F, Ruiz-Cabello F: Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 1998;47:113–120.
6.
Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997;272:28779–28785.
7.
Schaber JD, Fang H, Xu J, Grimley PM, Rui H: Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells. Cancer Res 1998;58:1914–1919.
8.
Kaneko S, Suzuki N, Koizumi H, Yamamoto S, Sakane T: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin Exp Immunol 1997;109:185–193.
9.
Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431–442.
10.
Yokosawa N, Kubota T, Fujii N: Poor induction of interferon-induced 2′,5′-oligoadenylate synthetase (2-5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 alpha. Arch Virol 1998;143:1985–1992.
11.
Heim MH: The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Eur J Clin Invest 1996;26:1–12.
12.
Lee CK, Bluyssen HA, Levy DE: Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity. J Biol Chem 1997;272:21872–21877.
13.
Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J: Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 1998;91:3017–3027.
14.
Evers BM, Ishizuka J, Townsend CJ, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393–406.
15.
Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines GK 3rd, Radosevich JA, Oberg K: Expression of p68 protein kinase and its prognostic significance during IFN-a therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046–2052.
16.
Kreivi JP, Zerivitz K, Akusjarvi G: Sequences involved in the control of adenovirus L1 alternative RNA splicing. Nucleic Acids Res 1991;19:2379–2386.
17.
Sprong H, Kruithof B, Leijendekker R, Slot JW, van Meer G, van der Sluijs P: UDP-galactose:ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum. J Biol Chem 1998;273:25880–25888.
18.
Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998;273:3838–3847.
19.
Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998;4:1449–1452.
20.
Wang S, Gebre-Medhin S, Betsholtz C, Stalberg P, Zhou Y, Larsson C, Weber G, Feinstein R, Oberg K, Gobl A, Skogseid B: Targeted disruption of the mouse phospholipase C beta3 gene results in early embryonic lethality. FEBS Lett 1998;441:261–265.
21.
Oberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110–120.
22.
Oberg K: Endocrine tumors of the gastrointestinal tract: Systemic treatment. Anticancer Drugs 1994;5:503–519.
23.
Oberg K, Eriksson B, Janson ET: Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 1994;3:64–69.
24.
Oberg K: The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992;3:35–41.
25.
Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumors. Acta Oncol 1991;30:519–522.
26.
Oberg K, Eriksson B, Janson ET: The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann NY Acad Sci 1994;733:471–478.
27.
Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH, Bergan A: Interferon-alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian Carcinoid Study. Scand J Gastroenterol 1995;30:789–796.
28.
Tiensuu Janson E, Ahlstrom H, Andersson T, Oberg KE: Octreotide and interferon alpha: A new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992;28A:1647–1650.
29.
Janson ET, Ronnblom L, Ahlstrom H, Grander D, Alm G, Einhorn S, Oberg K: Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial. Ann Oncol 1992;3:635–638.
30.
Weber-Nordt RM, Mertelsmann R, Finke J: The JAK-STAT pathway: Signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma 1998;28:459–467.
31.
Finbloom DS, Larner AC: Regulation of the Jak/STAT signalling pathway. Cell Signal 1995;7:739–745.
32.
Shuai K, Schindler C, Prezioso VR, Darnell JE Jr: Activation of transcription by IFN-gamma: Tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992;258:1808–1812.
33.
Krishnan K, Pine R, Krolewski JJ: Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner. Eur J Biochem 1997;247:298–305.
34.
Koster M, Hauser H: Dynamic redistribution of STAT1 protein in IFN signaling visualized by GFP fusion proteins. Eur J Biochem 1999;260:137–144.
35.
Haan S, Kortylewski M, Behrmann I, Muller-Esterl W, Heinrich PC, Schaper F: Cytoplasmic STAT proteins associate prior to activation. Biochem J 2000;345:417–421.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.